outsourcing drug discovery: your service partner from discovery through development

7/29/2019 Outsourcing Drug Discovery: Your service partner from discovery through development

http://slidepdf.com/reader/full/outsourcing-drug-discovery-your-service-partner-from-discovery-through-development 1/4

EMD Millipore is a division o Merck KGaA, Darmstadt, Germany

Trusted expertise

through every phase.Simpliy your outsourcing decisions –choose EMD Millipore as your service partnerrom discovery through development.



Featuring

As a leading innovator in ow cytometry technologies and services, EMD Millipore

understands the power o in-depth cell analysis or research and pharmaceuticaldevelopment. We combine our custom assay development, assay validation, and sample

processing capabilities with the most clinically established platorm, the BD FACSCanto™ II.

Our service portolio includes immunophenotyping, detection o intracellular and

extracellular markers, antigen binding assays and more.

Benefts:

• A powerul, exible analytical tool or drug efcacy measurement

•Scientifc expertise rom optimized sample preservation to robust validation

•Extensive data interpretation and processing

Learn more at www.emdmillipore.com/biomarkerservices

UbiquitinProfler™ Service removes the complexity o ubiquitin pathway drugdevelopment, and is the only service that enables you to explore the complete

ubiquitination cascade, including E3 ligase activity.

Benefts:

• Functional screening and profling assays or an expanding panel o E3 ligase cascades

to screen and profle inhibitors and enhancers

•Cascades consists o E1, E2 and E3 enzymes and biologically relevant substrates

•Led by the same experts who have run KinaseProfler™ services or over 10 years

Also available: related E1, E2, E3 and substrate products or unctional assays

Learn more at www.emdmillipore.com/ubiquitin

UbiquitinProfler™ Services

NEW! Flow Cytometry Assay Services



Pre-ClinicalHTS & Lead Discovery Phase 1 Phase 2 Phase 3 LaunchTarget Validation

Our service expertise spans the drug discovery process.

Screening and ProflingServices

Biochemical and cell-based

unctional assays or kinase, GPCR,

ion channel and ubiquitination

targets ● Proling services ●

Customized solutions through

assay development.

In Vitro Toxicity Studies

Industry-leading, unctional

proling against 125 GPCR, kinase,

phosphatase and ion channel targets.

Cell-Based Assay Services

GPCRProler® and IonChannelProler™ services integrate EMD Millipore’s stable GPCR and ion channel cell line products into unctional assays or small and large molecule

potency and selectivity proling ● GxP-compliant services or testing neutralizing antibody assays during tiered immunogenicity testing and in potency and stability testing

o biotherapeutics.

Biomarker Analysis Services

Protein and nucleic acid biomarker analysis ● RIA, ELISA, Luminex® xMAP® technology, electrochemiluminescence (ECL), Gyrolab® and fow cytometry services using the EMD Mill ipore portolio o assays or commercially

available kits rom any vendor ● Transer, develop and validate custom assays to meet your requirements ● Exploratory and GxP nucleic acid analysis using the latest qPCR and Pyrosequencing® instrumentation.

Biopharmaceutical Analysis Services

Experienced development and perormance o cell-based potency and l igand binding assays or impurity testing, batch

release and testing o stability samples ● Claim compliance to GMP or regulatory submission or as a non-regulatory study

under the same high quality standards ● Wide range o cell-based assays (e.g. ADCC, cell prolieration, receptor binding)

and ligand binding techniques including ELISA/RIA, Luminex® xMAP® Technology, surace plasmon resonance (Biacore™), ECL

and immunoblotting.

Pharmacokinetic Services

Industry-leading experience in the development and validation o PK/TK assays or the measurement o large molecules

and peptides ● Scalable solutions to meet your specic needs, rom routine sample analysis through to ull-service assay

development and validation.

Immunogenicity Services

Adhering to current FDA and EMA guidelines and AAPS white papers, we ollow a stepwise approach to measure anti-drug

antibody responses using ELISA/RIA, surace plasmon resonance, GyroLab®, ECL, DELFIA® and Nab analysis using cell-based

assays ● We transer, develop and validate methods and evaluate several platorms to ensure optimal data quality ● With

unsurpassed industry experience, EMD Millipore provides the technical expertise, quality assurance and peace o mind

that are essential when considering a partner or research, preclinical through to clinical regulated assay development and

sample analysis on any scale.

www.emdmillipore.com/discdev

From discovery throughdevelopment.

EMD Millipore is your premier service provider or

condently advancing your drug pipeline rom discovery

to market. We extend your capabilities by combining our

scientic knowledge, regulatory expertise and fexibility,

with the trusted, relevant inormation required or your drug

discovery and development needs.



www.emdmillipore.com/discdev

EMD Millipore, the M Mark, KinaseProfler, IonchannelProfler and UbiquitinProfler are

trademarks o Merck KGaA, Darmstadt, Germany. GPCRProfler is a registered trademark o

Merck KGaA, Darmstadt, Germany. Luminex and xMAP are registered trademarks o Luminex

Corporation. Biacore is a trademark o GE Healthcare Biosciences AB. Gyrolab is a registeredtrademark o Gyros AB. DELFIA is a registered trademark o PerkinElmer, Inc. Pyrosequencing is a

registered trademark o Qiagen. FACSCanto is a trademark o BD Biosciences.

Lit code # PF3332EN00 Rev. A DD SBU-12-06547 ROSE

9/2012 ©2012 EMD Millipore Corporation, Billerica, MA USA. All rights reserved.

To Place an Order or ReceiveTechnical Assistance please contactour scientiic development group at:

[email protected]

Get Connected!

Join EMD Millipore Bioscience on your avorite socialmedia outlet or the latest updates, news, products,innovations and contests!

acebook.com/EMDMilliporeBioscience

twitter.com/EMDMilliporeBio

outsourcing drug discovery: your service partner from discovery through development

Documents